1
Barta Nancy Sue, Campbell Brian Michael, Dounay Amy Beth, Gray David Lawrence Firman, Zorn Stevin Howard: Phenoxy-pyridyl derivatives. Pfizer, Barta Nancy Sue, Campbell Brian Michael, Dounay Amy Beth, Gray David Lawrence Firman, Zorn Stevin Howard, FULLER Grover F Jr, July 2, 2009: WO/2009/081259 (17 worldwide citation)

Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula (I), as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.


2
Barta Nancy Sue, Glase Shelly Ann, Gray David Lawrence Firman, Reichard Gregory Adam, Simons Lloyd Jerome, Xu Wenjian: Substituted morpholine compounds for the treatment of central nervous system disorders. Warner Lambert Company, Barta Nancy Sue, Glase Shelly Ann, Gray David Lawrence Firman, Reichard Gregory Adam, Simons Lloyd Jerome, Xu Wenjian, WOOD David J, November 10, 2005: WO/2005/105763 (7 worldwide citation)

This invention relates to compounds of the formulae (I), (II), (III), wherein R'- Re, A, X, and Z are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.


3
Barta Nancy Sue, Schwarz Jacob B, Thorpe Andrew J, Wusstrow David J: Amino acids with affinity for the alpha-2-delta protein. Warner Lambert Co, January 11, 2006: EP1614675-A2

The invention relates to compounds of the formula II, III and IV, compositions comprising them and their use in the treatment of, inter alia, pain.


4
Barta Nancy Sue, Schwarz Jacob Bradley, Thorpe Andrew John, Wustrow David Juergen: Amino acids with affinity for the alpha-2-delta-protein. Warner Lambert Co, January 5, 2005: EP1492761-A2

This invention relates to certain beta-amino acids that bind to the alpha-2-delta (alpha2delta) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.


5
Guo Chuangxing, Augelli Szafran Corinne E, Barta Nancy Sue, Bender Steven Lee, Bigge Christopher Franklin, Caprathe Bradley William, Chatterjee Arindam, Deal Judith, Dong Liming, Fay Lorraine Kathleen, Hou Xinjun, Hudack Raymond Andrew Jr: Heterobicycles fkbp-ligands. Agouron Pharma, June 2, 2004: EP1423119-A1

Diazabicyclo[3.3.1]nonane derivatives that inhibit the peptidyl-prolyl isomerase enzyme activity associated with FK-506 binding proteins (FKBP) are described for treating neurological disorders. Also described are compounds useful for preparing such inhibitors.


6

7

8
Barta Nancy Sue, Schwarz Jacob B, Thorpe Andrew J, Wusstrow David J: Amino acids with affinity for the alpha-2-delta protein. Warner Lambert Co, zhang bengyuan zhao renlin, August 16, 2006: CN200610007028

This invention relates to certain beta-amino acids that bind to the alpha-2-delta (alpha2delta) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.


9
Barta Nancy Sue, Schwarz Jacob Bradley, Thorpe Andrew John, Wustrow David Juergen: Acides amines a affinite vis-a-vis de la proteine .alpha.-2-.delta., Amino acids with affinity for the .alpha.-2-.delta.-protein. Warner Lambert Company, Warner Lambert Company, Smart & Biggar, February 15, 2011: CA2480872

This invention relates to certain .beta.-amino acids that bind to the alpha-2-delta (.alpha.2.delta.) subunit of a calcium channel. These compounds and their pharmaceutically acceptable salts are useful in the treatment of a variety of psychiatric, pain and other disorders.


10
Barta Nancy Sue, Colbry Norman Lloyd, Hudack Raymond Andrew Jr, Lin Kristin Knapp, Schwarz Jacob Bradley, Thorpe Andrew John, Wustrow David Juergen, Zhu Zhijian: Tetrazole and oxadiazolone substituted beta-amino acid derivatives. Warner Lambert Co, December 14, 2005: EP1603890-A1

This invention relates to novel tetrazole and oxadiazalone beta-amino acids derivatives of the formula (I, II), wherein G is (III, IV) wherein R through R are defined as in the specification, pharmaceutical compositions containing them and their use for the treatment of various central nervous syste ...